We're looking for early-adopters for Cofactor's Paragon Assay. Interested in learning more?
Characterizing clinical samples using flow cytometry is difficult, expensive, and inconvenient.
We're using the power of RNA-seq to change the way clinical researchers use immuno-oncology.
Cofactor Paragon reports on the cellular components of the tumor micro-environment. 32 cell types are reported and provide valuable insight in studies aimed at understanding how the micro-environment and the immune activity plays a key role in efficacy of treatment.
Cofactor's Paragon is set to launch in early 2017.